SeeThruEquity Initiates Coverage on Viatar CTC Solutions (OTCQB: VRTT) with Price Target of $4.94

NEW YORK, NY / ACCESSWIRE / July 29, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage on Viatar CTC Solutions (OTCQB: VRTT) with a 12 month price target of $4.94.

The report is available here: VRTT Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

Viatar CTC Solutions Inc. is a medical technology company focused on treatment of patients with metastatic cancer. The company’s lead product, the Viatar(TM) Therapeutic Oncopheresis System, removes circulating tumor cells (CTCs) from whole blood using label-free cross-flow filtration. Pending regulatory approval, the product is targeted for 2016. It would be used as a periodic therapy to improve overall survival for a wide range of solid tumor types such as lung, breast, and colon, prostate and gastric cancers. Viatar’s proprietary technology also powers their liquid biopsy products, which provide a significantly greater quantity and purity of CTCs for personalized medicine by genetic testing companies, researchers and medical oncologists.

“We believe the company is on a successful path as they seek to provide effective and cost-efficient products for the cancer market,” stated Ajay Tandon, CEO of SeeThruEquity. “We are initiating coverage with a 12-month price target of $4.94 per share.”

Additional highlights from the report are as follows:

Targeting metastatic cancer market

Viatar is targeting two of the hottest markets right now: the metastatic cancer market and the personalized medicine market. Viatar’s Therapeutic Oncopheresis System addresses a large and under-served market: metastatic cancer. According to GBI research, the global oncology therapeutics market was valued at $33.3bn in 2010. Projected with a moderate growth rate of 5.7%, the oncology therapeutics market is expected to reach $48.9bn by 2017. In addition, according to the World Health Organization (“WHO”), the global incidence of new cancer cases in 2012 was estimated at approximately 14.1mn and 8.2mn cancer deaths annually. In American, European and Western Pacific regions, cancer is the second leading cause of death.

The therapeutic Oncopheresis System will be a less expensive product

Viatar’s Therapeutic Oncopheresis System will be much less expensive than FDA-approved targeted therapies. According to an article published by Mayo Clinic Proceedings, the handful of recently approved drugs which show some efficacy in targeting metastasized cancers cost upwards of $100,000 per patient and yet provide only a scant few months of longevity over legacy chemotherapy drugs. The annual cost of chronic care of Viatar’s Therapeutic Oncopheresis System will land at around $15,000. The company expects to launch the system in 2016 with a CE mark in Canada and Europe.

Top CTC removal technology

The key Viatar technology aspects include filtering out CTCs using label-free cross flow filtration with precise pores and blood flow rates, exploiting size, shape and deformation differences between CTCs and normal blood components. The company also holds five pending patents with coverage until 2035.

Management team well versed in public market dynamics

Viatar CTC Solutions Inc. is publicly traded in the OTCQB Market. The company was founded in 2008 and headquartered in Lowell, MA. The Viatar management team has an impressive record of building, running and growing life science technology companies. Prior to serving as Chairman and founder of Viatar, Mr. Reich was and President and Co-CEO of Inamed Corp., a company that provides various medical aesthetic products, in which their market cap grew from $25mn to $500mn under his leadership.

Initiate coverage with a price target of $4.94

Our analysis indicates a fair value estimate of $4.94 per share.

Please review important disclosures on our website at www.seethruequity.com.

About Viatar CTC Solutions Inc.

Viatar CTC Solutions Inc. is a medical technology company focused on the treatment of patients with metastatic cancer. The company’s lead product, the Viatar(TM) Therapeutic Oncopheresis System, removes circulating tumor cells from whole blood using label-free cross-flow filtration. With pending regulatory approval targeted for 2016, it will be used as a periodic therapy to improve overall survival for a wide range of solid tumor types such as lung, breast, colon, prostate and gastric cancers. This proprietary technology also powers the company’s liquid biopsy products, which are collection systems for use by genetic testing companies, researchers and medical oncologists that provide a greater quantity and purity of circulating tumor cells for their molecular analysis and personalized medicine objectives.

For more information, please visit www.viatarctcsolutions.com.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 430918